News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Popular Weight-Lifting Supplement May Slow Huntington Disease, Massachusetts General Hospital Study



2/10/2014 7:44:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease (HD) reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging showed a treatment-associated slowing of regional brain atrophy, evidence that creatine might slow the progression of presymptomatic HD. The Massachusetts General Hospital (MGH) study also utilized a novel design that allowed participants – all of whom were at genetic risk for the neurodegenerative disorder – to enroll without having to learn whether or not they carried the mutation that causes HD.

Hey, check out all the research scientist jobs. Post your resume today!

Read at News Release
Read at MedicalXpress
Read at News Release
Read at ScienceDaily
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES